Business
-
According to Microbion Corporation, the company has received up to $1.8 million from the Cystic Fibrosis Foundation to fund toxicology studies to support an IND for the company’s pravibismane inhalation suspension for the treatment of… Read more . . .
-
Seelos Therapeuticse has announced an additional amendment to its 2018 agreement with Vyera Pharmaceuticals (now Phoenixus) in order for the company to repurchase 9% of royalties payable on any future net sales of SLS-002 intranasal… Read more . . .
-
The Central European Biotech Incubator and Accelerator (CEBINA) has announced a partnership with Ursapharm Arzneimittel to repurpose Ursapharm’s Pollival azelastine nasal spray for the treatment of COVID-19. In July 2020, CEBINA announced that it had filed a… Read more . . .
-
The US Patent and Trademark Office has issued US Patent No. 10,874,818, titled “Aerosol Delivery System,” covering technology used in the delivery of Windtree Therapeutics’ Aerosurf aerosolized KL4 surfactant, Windtree said. The company redesigned the… Read more . . .
-
Tonix Pharmaceuticals announced that it has licensed technology related to oxytocin-based therapies for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from the French National Institute of Health and Medical Research (Inserm).… Read more . . .
-
According to Protalix BioTherapeutics, the company has signed an agreement with SarcoMed USA giving SarcoMed exclusive worldwide license agreement for Protalix’s PRX-110 inhaled alidornase alfa for the treatment of respiratory diseases including pulmonary sarcoidosis and pulmonary… Read more . . .
-
Hangzhou Chance Pharmaceuticals is paying an undisclosed amount up front, plus milestone payments and royalties, to acquire the rights to develop and commercialize Aerami Therapeutics’ AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension… Read more . . .
-
Herantis Pharma has signed an agreement with nanoparticle technology company Nanoform Finland to try out Nanoform’s biologics nanoparticle technology for intranasal formulations of CDNF (cerebral dopamine neurotrophic factor). Nanoform launched its nanoparticle technology for biologics… Read more . . .
-
AuraVax Therapeutics, which is developing an intranasal vaccine against COVID-19, announced that it has acquired an exclusive license for IP related to intranasal respiratory vaccine technology and STING agonist technology from the University of Houston. Earlier… Read more . . .
-
Revelation Biosciences said that it has closed a private placement financing with gross proceeds of $4.4 million that it plans to use for development of two pipeline products, including its REVTx-99 intranasal phosphorylated hexaacylated disaccharide… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden